J clin oncol 25:85-90.2007
WebMore than 90 percent of patients with newly diagnosed germ-cell tumors are cured, ... J Natl Cancer Inst 1993;85: 60-62. Crossref; Web of Science; Medline; ... J Clin Oncol 1995;13: 274-282 ... WebApr 8, 2024 · Int J MS Care 2007; 9: 126–130. Crossref. Google Scholar. 12. Kessels E, Husson O, van der Feltz-Cornelis CM. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. ... 25: 1009–1017. Crossref. PubMed. Google Scholar. 17. ... J Clin Oncol 2014; 32(4): 335–346. Crossref. PubMed. …
J clin oncol 25:85-90.2007
Did you know?
WebApr 14, 2024 · Objective: The current molecular classification system for gastric cancer covers genomic, molecular, and morphological characteristics. Non-etheless, classification of gastric cancer based upon DNA damage repair is still lacking. Here, we defined DNA damage repair-based subtypes across gastric cancer and identified clinicopathological, … WebAug 12, 2024 · J Clin Oncol 25: 85-90, 2007 Link, Google Scholar: 66. Feldman DR, Sheinfeld J, Bajorin DF, et al: TI-CE high-dose chemotherapy for patients with previously treated …
WebApr 12, 2024 · Complications occurring either within 30 or 90 days of surgery were classified using the Clavien-Dindo scale (Supplementary Table S2). 17. Dindo D. ... specific causes … WebAt the second screening visit, which is scheduled within 7 days before randomisation, patients are invited for collection of further measurements: (1) height, weight, body temperature, blood pressure, heart rate, respiratory rate and performance status (PS) assessed using the Eastern Cooperative Oncology Group (ECOG) method; (2) complete …
WebJ Clin Oncol 25:579-586. © 2007 by American Society of Clinical Oncology INTRODUCTION Standardizedresponsecriteriaprovideuniformend points for clinical trials, allowing for … WebApr 5, 2024 · 40-year cumulative all-cause mortality was 23·3% (95% CI 22·7–24·0), with 3061 (51·2%) of 5916 deaths from health-related causes. Survivors 40 years or more from …
WebJapanese Journal of Clinical Oncology Oxford Academic Latest Issue Volume 53 Issue 4 April 2024 Impact Factor 2.925 5 year Impact Factor 2.864 Editor-in-Chief Hideo Kunitoh Editorial Board New guidelines for clinical research
WebApr 11, 2024 · IrEC is one of the most frequent irAEs associated with ICI use, affecting 5%-17% of patients treated with anti–PD-L1 therapy, 35%-40% of patients treated with anti–cytotoxic T-cell lymphocyte-4 (CTLA-4) therapy, and 32%-50% of patients receiving this combination. 6,8,9 IrEC is the irAE that most commonly leads to treatment interruption or … can you listen to your own lungsWebJun 1, 2007 · Purpose: We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, and paclitaxel in advanced urothelial carcinoma patients and prospectively evaluated human epidermal growth factor receptor-2 (Her-2/neu) overexpression rates. Patients and methods: bright touch maids marietta gaWebApr 11, 2024 · At present, the main therapeutic strategy for platinum-resistant patients with recurrent ovarian cancer is systemic chemotherapy, such as polyethylene glycol liposome doxorubicin (PLD) ( 6, 7) and topotecan ( 6 ). The effective rate in most patients is 10–30% ( 7 ). The effective rate of weekly paclitaxel chemotherapy is 25–55% ( 8 ). bright toward industrial 代理店WebIn 2008, an estimated 54,360 people in the United States will be diagnosed with renal cell cancer (RCC) and more than 13,000 will die from this disease.1Approximately 20% of patients will have locally advanced disease at diagnosis and 25% will have metastatic disease at diagnosis.2,3 bright to wangarattaWebAnn Surg Oncol. 2024;25(7):1783–1785. 27. Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer … bright toursWebIntroduction. Pancreatic cancer is a major cause of cancer-related mortality in western countries and it is projected to emerge as the second leading cause of cancer-related deaths in the United States by 2030. 1 Its prognosis is extremely poor, with a 5-year survival rate for all patients with pancreatic adenocarcinoma of approximately 6–8%. 2–5 The vast … bright to wangaratta busWebApr 12, 2024 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, … bright touchscreen panel mount